Ovarian Cancer Clinical Trials

2174 clinical trials for Ovarian Cancer across international registries, including 371 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) — RECRUITING · PHASE3
• A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) — RECRUITING · PHASE3
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer — RECRUITING · PHASE2
• Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) — RECRUITING · PHASE2
• Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer — RECRUITING · PHASE1
• Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer — RECRUITING · PHASE1
• Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers — RECRUITING · PHASE1
• Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — RECRUITING · PHASE2
• Ovarian Cancer Identification on CT Using Deep Learning — RECRUITING
• A Study of PHST001 in Advanced Solid Tumors — RECRUITING · PHASE1
• A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies — RECRUITING · PHASE1
• A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression — RECRUITING · PHASE3
• 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors — RECRUITING · NA
• A Study of MGC026 in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer — RECRUITING · PHASE1
• The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) — RECRUITING · PHASE1
• A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) — RECRUITING · PHASE3
• Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. — RECRUITING · PHASE1
• Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic Malignancies — RECRUITING
• A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation — RECRUITING · PHASE1
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — RECRUITING · PHASE3
• A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — RECRUITING · PHASE2
• IDOV-Immune for Advanced Solid Tumors — RECRUITING · PHASE1
• Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer — RECRUITING · PHASE3
• Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors — RECRUITING · PHASE1
• Distance-Based Exercise to Preserve Function and Prevent Disability — RECRUITING · NA
• Study Evaluating Safety, Tolerability, and Metabolism of Niraparib — RECRUITING · PHASE4
• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies — RECRUITING · PHASE1
• Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery — RECRUITING · PHASE3
• Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE1
• Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer — RECRUITING · PHASE3
• Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis — RECRUITING
• Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology — RECRUITING
• A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer — RECRUITING · PHASE2
• Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy — RECRUITING · PHASE3
• A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination with Bevacizumab in Adult Participants with Ovarian Cancer — RECRUITING · PHASE1
• Study to Assess Prevalence of the Folate Receptor Alpha (FRa) in Adult Female Participants With Ovarian Cancer in Intercontinental (InterCon) Countries — RECRUITING
• Clinical Pre-screening Protocol for Ovarian Cancer — RECRUITING
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer — RECRUITING · NA
• Normethermic Intraperitoneal Chemotherapy - a Novel Concept for Local Treatment of the Elderly and Fragile Women With Advanced Ovarian Cancer? — RECRUITING · PHASE1
• Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer — RECRUITING · PHASE1
• A Study of Isoquercetin in People With Ovarian Cancer — RECRUITING · PHASE2
• The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons — RECRUITING
• AOH1996 for the Treatment of Refractory Solid Tumors — RECRUITING · PHASE1
• A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy — RECRUITING · PHASE2
• Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer — RECRUITING · PHASE1
• Identifying Genetic Targets in Gynecological Tumors — RECRUITING

Refine this search